Back to research

Research paper

Closed-loop modulation of sleep in children undergoing intracranial recordings

Phase-targeted auditory stimulation (PTAS) study applying closed-loop slow-wave enhancement in children. Shows feasibility and cognitive/sleep-quality signals in pediatric populations.

Indexed context

Wong SY, et al.

ptasclosed-loopsleep-modulationslow-wavepediatric2026

Markdown path

content/research/papers/2026-wong-ptas-closed-loop-sleep-children.md

Findings

Phase-targeted auditory stimulation (PTAS) study applying closed-loop slow-wave enhancement in children. Shows feasibility and cognitive/sleep-quality signals in pediatric populations.

Why it may matter for Levi

Novel non-pharmacologic option for slow-wave sleep modulation - directly relevant to the Tononi-Cirelli sleep-homeostasis framework already in the corpus. Not yet clinically available for DEE-SWAS but worth tracking as an emerging modality. Adds to the neuromodulation options tier below rapalogs/IVIG/KD.

Paper text

Wong et al. (2026) — Phase-Targeted Auditory Stimulation (PTAS) in pediatric epilepsy

Source

  • Cell Reports Medicine 7(1):102538, January 2026.

Why in corpus

Landmark 2026 study demonstrating closed-loop auditory stimulation timed to endogenous slow oscillations can simultaneously modulate sleep architecture, suppress interictal epileptiform discharges, and enhance cognition — addressing the core mechanism of DEE-SWAS.

Key findings

  • 27 children undergoing epilepsy monitoring with simultaneous scalp, intracranial, and thalamic recordings.
  • Closed-loop auditory stimulation system delivers stimuli phase-locked to endogenous slow oscillations during NREM sleep.
  • Results:
    • Slow-wave sleep power: significantly enhanced, maximal in thalamus, frontal, and auditory regions
    • Interictal epileptiform discharges (IEDs): suppressed from 0.4 spikes/min to <0.1 spikes/min
    • Response inhibition accuracy: improved from 76% to 95%
  • First direct intracranial evidence that closed-loop auditory stimulation can simultaneously modulate sleep architecture, suppress pathological activity, and enhance cognition.

Levi-relevant takeaways

  • Most mechanistically aligned non-invasive candidate therapy for DEE-SWAS. Addresses the Synaptic Homeostasis Hypothesis directly — not a secondary mechanism.
  • Currently experimental and requires specialized monitoring; not yet a clinically available therapy for Levi.
  • Worth tracking as a candidate for a future trial-access or research-protocol referral if the technology advances to ambulatory pediatric deployment.
  • Mayer/Erlanger, and the handful of academic sleep-labs conducting PTAS research, are reasonable long-horizon outreach targets.
  • Supports the broader framing that sleep-optimization interventions have mechanistic grounding in DEE-SWAS — not just general-pediatric sleep-hygiene recommendations.

Relationship to differential/treatments

  • Does not currently move Levi's treatment rank — PTAS is not accessible clinical therapy yet.
  • Reinforces the rank-0 structural priority: durable suppression of sleep-activated SWAS enables normal synaptic downscaling and cognitive recovery. PTAS is one future mechanism among several (corticosteroids, benzodiazepines, surgery) for achieving that.